Nonsteroidal MRA Drug Cuts Risks in Earlier Diabetic Kidney Disease
Finerenone (Kerendia) prevents cardiovascular (CV) and some renal events in type 2 diabetes patients with earlier stages of kidney disease, the FIGARO-DKD trial showed. In the trial’s stage 1 to 4 kidney disease patients with moderate-to-severe albuminuria, the nonsteroidal mineralocorticoid receptor antagonist (MRA) reduced the composite of CV death, nonfatal myocardial infarction or stroke, or […]
Does CPAP Therapy for Sleep Apnea Really Have Heart Benefits?
Despite the widespread belief that obstructive sleep apnea (OSA) causes cardiovascular events like strokes and heart attacks, there is actually no good evidence that treating OSA lowers the risk of such cardiovascular outcomes. Observational data showing that OSA is associated with cardiovascular outcomes like atrial fibrillation (Afib), stroke, cardiovascular death, and myocardial infarction (MI) have […]